drugset

drugset / Trial / NCT00357825

A Trial Assessing The Effectiveness and Safety of [S,S]-Reboxetine in Patients With Fibromyalgia

NCT00357825 ↗

Phase 2 Completed 246 enrolled Pfizer

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety and effectiveness of \[S,S\]-Reboxetine in patients with fibromyalgia.

Timeline

Start: 2006-08
Primary completion: 2007-03
Completion: 2007-03

Publications

Arnold LM, Chatamra K, Hirsch I, Stoker M. Safety and efficacy of esreboxetine in patients with fibromyalgia: An 8-week, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2010 Aug;32(9):1618-32. doi: 10.1016/j.clinthera.2010.08.003.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	[S,S]-Reboxetine	Unknown	8 mg	—

Indications

No indication recorded.